Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maevskaya

Showing results (21-30 of 102) with videos related to

Pageof 11
Sort By:
Drugs - Real World Outcomes|May 16, 2021
Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational StudiesVladimir T Ivashkin, Marina V Maevskaya, Elena N Shirokova, et al.
World Journal of Gastroenterology|March 29, 2021
Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver diseaseMaria Nadinskaia, Marina Maevskaya, Vladimir Ivashkin, et al.
European Journal of Gastroenterology & Hepatology|May 16, 2018
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV)Vasily Isakov, Dzmitry Paduta, Rolando M Viani, et al.
Journal of Viral Hepatitis|September 13, 2002
A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis CY Lurie, F Nevens, Z G Aprosina, et al.
Clinical and Translational Gastroenterology|July 18, 2024
Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri ( Limosilactobacillus reuteri ) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled TrialVladimir Ivashkin, Igor Maev, Elena Poluektova, et al.
Terapevticheskii Arkhiv|February 1, 2019
Differential diagnosis of ascites in internal medicine: clinical caseI N Tikhonov, M S Zharkova, M V Maevskaya, et al.
Minerva Gastroenterologica E Dietologica|February 13, 2018
Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver diseaseVladimir T Ivashkin, Marina V Maevskaya, Zhanna D Kobalava, et al.
Journal of Viral Hepatitis|November 18, 2015
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirinG R Foster, P Ferenci, T Asselah, et al.
Terapevticheskii Arkhiv|December 21, 2020
[Antibiotic resistance of Helicobacter pylori in the European part of the Russian Federation: first results]I V Maev, D N Andreev, V M Govorun, et al.
Journal of Hepatology|January 7, 2015
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infectionPeter Ferenci, Tarik Asselah, Graham R Foster, et al.
Pageof 11

Showing results (21-30 of 102) with videos related to

Sort By:
Pageof 11
Drugs - Real World Outcomes|May 16, 2021
Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational StudiesVladimir T Ivashkin, Marina V Maevskaya, Elena N Shirokova, et al.
World Journal of Gastroenterology|March 29, 2021
Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver diseaseMaria Nadinskaia, Marina Maevskaya, Vladimir Ivashkin, et al.
European Journal of Gastroenterology & Hepatology|May 16, 2018
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV)Vasily Isakov, Dzmitry Paduta, Rolando M Viani, et al.
Journal of Viral Hepatitis|September 13, 2002
A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis CY Lurie, F Nevens, Z G Aprosina, et al.
Clinical and Translational Gastroenterology|July 18, 2024
Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri ( Limosilactobacillus reuteri ) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled TrialVladimir Ivashkin, Igor Maev, Elena Poluektova, et al.
Terapevticheskii Arkhiv|February 1, 2019
Differential diagnosis of ascites in internal medicine: clinical caseI N Tikhonov, M S Zharkova, M V Maevskaya, et al.
Minerva Gastroenterologica E Dietologica|February 13, 2018
Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver diseaseVladimir T Ivashkin, Marina V Maevskaya, Zhanna D Kobalava, et al.
Journal of Viral Hepatitis|November 18, 2015
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirinG R Foster, P Ferenci, T Asselah, et al.
Terapevticheskii Arkhiv|December 21, 2020
[Antibiotic resistance of Helicobacter pylori in the European part of the Russian Federation: first results]I V Maev, D N Andreev, V M Govorun, et al.
Journal of Hepatology|January 7, 2015
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infectionPeter Ferenci, Tarik Asselah, Graham R Foster, et al.
Pageof 11